Piramal Stays The M&A Course; Snaps Up Niche Mallinckrodt Assets

India’s Piramal group continues its buying spree, snapping up Mallinckrodt’s intrathecal therapy business, as it seeks limited competition niches to plough deeper into the $20bn-plus global generic injectable hospital drugs market.